Company

Bank

Analyst

Coverage

Opinion

Wk chg

6/15 cls

Basilea Pharmaceutica AG (SIX:BSLN)

Jefferies

Philippa Gardner

Price target

Hold

3%

CHF44.05

Gardner raised her target to CHF51 from CHF45 after Basilea granted Stiefel Laboratories Inc. exclusive, worldwide rights to its only marketed drug, eczema therapy Toctino alitretinoin (see B6). She said "Toctino will likely be more successful in the hands of a larger dermatology player, such as Stiefel." Stiefel is a subsidiary of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK).

Dendreon Corp. (NASDAQ:DNDN)

Summer Street

Ling Wang

New

Buy

23%

$7.76